Overview of the global immunodiagnostics market
The global immunodiagnostics market is anticipated to grow at a steady rate and will post a CAGR of close to 8% during the forecast period. The increasing adoption of point-of-care testing (POCT) will drive the growth prospects for the global immunodiagnostics market until the end of 2021. Some of the life-threatening conditions that need serious attention include sepsis and acute cardiac infarction. Such serious conditions with high mortality rate drive the necessity for POCT, which, in turn, boosts the demand for immunodiagnostics testing. One of the areas of focus for traditional and non-traditional healthcare companies are POCT for cardiovascular biomarkers. Also, POCT is fast, accurate, portable, and simple to interpret, which helps healthcare providers in alternative healthcare settings. Moreover, the cost of POCT is very low because of its small capillary tubes that need fewer reagents.
In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market for the next four years. The demand for diagnostic products and services in the region is growing because of factors such as the fast-growing elderly population and the high prevalence of chronic and infectious diseases. Also, the rising awareness of the diseases among consumers compels them to undergo regular tests and check-ups, which improves the sales of immunodiagnostic products in the US. Furthermore, increased FDA approval, shift to point-of-care (POC) rapid diagnostic tests and a rise in laboratory
Overview of the global genomics biomarkers market
The global genomics biomarkers market is anticipated to grow at a steady rate and will post a CAGR of close to 18% during the forecast period. The increasing instances of low-cost clinical trials in developing countries will drive the growth prospects for the global genomics biomarkers market until the end of 2021. This globalization of clinical trials has been credited to numerous components that include organized trials, the willingness of members facilitating the enrollment, accessibility of qualified local investigators, enhanced opportunities in various Tier 2 and Tier 3 countries, and lower expenses of clinical trials in developing nations. Some of the other factors responsible for the increasing preference for disease-based genomic biomarkers testing includes the faster and precise analysis of diseases and potential lowering in volume and time involved in clinical trials.
In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market for the next four years. One of the major factor responsible for the market’s growth in the region is clinical research activities provided by a large number of manufacturers and distributors to other countries such as Brazil, Mexico, and few Tier 3 countries. According to the industry research report, increasing investments in the healthcare sector to provide the highest quality and effective treatment will drive the market’s growth in the region during the forecasted region.
Competitive landscape and key vendors
The global genomics biomarkers market is highly competitive and fragmented due to the presence of a large number of vendors across the globe. These vendors increasingly form partnerships to develop
Overview of the global HPV testing market
The global human papillomavirus (HPV) testing market is anticipated to grow rapidly and will post a CAGR of more than 16% during the forecast period. The increasing trend of early detection to prevent the growing prevalence of cervical cancer will drive the growth prospects for the global HPV testing market until the end of 2020. The increasing adoption of HPV tests among women will enable the early detection of high-risk HPV genotypes such as HPV 16, 18, 31, 33, 45, and others. Also, since the government has released guidelines in various countries recommending women aged 26-65 years to undergo HPV testing for the early detection of cervical cancer, the adoption of HPV testing is increasing. Some of the countries who have benefitted from early detection due to government regulations include regions such as Americas, EMEA, and APAC. Since the Affordable Care Act in the US has increased the adoption of HPV testing, around 75% of women have undergone early diagnosis. Similarly, the government initiatives in Germany to invite women aged between 20 and 60 in 2018 will drive the adoption rate of the testing kit. Furthermore, the changes made in National Cervical Screening Program of 2016 in New Zealand, APAC, to include women aged between 20 to 25 years will boost awareness about cervical cancer among women.
In terms of geography, the Americas accounted for the maximum market share during 2015 and will continue to dominate the market for the next few years. One of the major factors responsible for the market’s growth in North America is the growing number of cervical cancer patients, which accounts for more than 13,000 cases each year. Also, the government initiatives in various countries such as the US, Canada, and Brazil, the awareness and adoption of
Overview of the global cervical cancer diagnostic testing market
The global cervical cancer diagnostic testing market is anticipated to grow at a steady rate and will post a CAGR of close to 7% during the forecast period. The growing adoption of human papillomavirus (HPV) testing will drive the growth prospects for the global cervical cancer diagnostic testing market until the end of 2020. HPV may progress from a low-grade disease to a high-grade disease. It is sometimes associated with cervical cancer, vaginal, vulvar, and penile carcinomas, anal carcinomas, and cancer of the larynx and aerodigestive tract. HPV tests are also used as a primary screening diagnostic tool to diagnose cervical cancer. For instance, pap smear, which is a screening procedure for cervical cancer, ensures a better detection of high-risk HPV types 16 and 18.
In terms of geography, the Americas accounted for the maximum market share during 2015 and will continue to dominate the market for the next few years. The major factors responsible for the high market share of the region is the widespread awareness and favorable reimbursement options associated with the advanced cervical cancer screening tests. Furthermore, the increasing rate of investments in R&D and new product launches by the leading vendors in the countries like the US and Canada will further drive this market’s growth in the region.
Competitive landscape and key vendors
The global cervical cancer diagnostic testing market is highly fragmented and dynamic due to the presence of large, medium, and small sized companies. The market is also anticipated to witness an intensely competitive environment during the forecast period due to factors such as advancements in technology and
Outlook of the global nucleic acid testing market
The global market for nucleic acid testing will grow at a CAGR of nearly 10% by 2020. According to the analysts, eminent factors like the higher adoption rate of molecular point-of-care (POC) testing will aid in the strong growth of this market during the forecast period. POC testing provides immediate results in non-laboratory settings to support more patient-centered approaches to healthcare delivery. The sensory technology enables the rapid analysis of blood samples. In the molecular diagnosis field, there is a higher adoption for POC testing systems as it helps in glucose self-testing. Also, due to the high cost of clinical diagnostic devices, the preference for molecular POC testing has increased.
In terms of geography, the nucleic acid testing market will witness rapid growth in the Americas. The market in this region is dynamic, with the presence of more than 20 established companies that compete for the sales of nucleic acid testing systems and reagents. The market in this region also provides significant opportunities for vendors, particularly in the US, as private and government research institutes and pharmaceutical companies are extensively adopting genome engineering, next-generation sequencing and gene editing technologies.
Competitive landscape and key vendors
The global nucleic acid market is in nascent stage and is characterized by the presence of large (tier 1), medium (tier 2) and small sized companies (tier 3) companies. Most of the top tier companies are present in the Americas and Western Europe. However, in APAC (such as China) there are many local vendors that account for a major share of the market in some areas. Factors such as advances in technology and new product launches also help in increasing the level of competition among vendors.
Top vendors in this market are -
Overview of the global hospital-acquired urinary tract infection testing market
Technavio’s market research analyst predicts the global hospital-acquired urinary tract infection testing market to grow at a CAGR of around 19% between 2016 and 2020. Urinary tract infection occupies the largest share in the HAIs category, and the number is constantly growing. This has encouraged several vendors to develop innovative testing products that will subsequently augment the demand for hospital-acquired urinary tract infection testing products. Several technological advancements have enhanced the testing procedures for urinary tract infection, as they are more precise, sensitive, generate faster outcomes, and provide a broader range of pathogen detection as compared with the most traditional methods. Moreover, the innovative techniques in bioinformatics and software programs help manage a massive amount of data and offer better-quality results from tests such as molecular diagnostics. These methods provide initiation of infection control practices, optimization of treatment selection, reduced hospital stay, and improved surveillance of infectious diseases. Also, hospitals are setting up infection control committees that focus on only HAIs. Such infection control committee is responsible for the evaluation and planning of evidence-based practice, resource allocation, and prioritization of matters related to infection control.
Geographically, the Americas dominated the market and accounted for the largest market share in 2015. The high prevalence of infectious diseases, leading to the increased demand for diagnostic products and services and focus on disease management has propelled market growth in this region. The US is the largest revenue contributor for the hospital-acquired UTI testing market in the Americas owing to the massive sales of
In-vitro diagnostics is one of the fastest-growing sectors in healthcare. Cost-containment strategies by healthcare entities have led to an increased focus on early diagnosis, preventive medicine, and personalized medicine.
This move towards preventive and personalized medicine is driving the adoption of in-vitro diagnostics, and vendors are focusing on developing tests for a wide range of applications for hospitals and laboratories, as well as for home care. The presence of a high number of market participants has significantly intensified competition.